Wexford Capital’s Structure Therapeutics GPCR Stock Holding History

Wexford Capital’s Portfolio GPCR Stock Details GPCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$736K	Hold	13,709	–	–	0.09%	80
2026 Q1	$661K	Sell	13,709 -1,126	-8%	-$77.1K	0.1%	70
2025 Q4	$1.03M	Buy	+14,835	New	+$606K	0.2%	75
2025 Q2	–	Sell	-30,102	Closed	-$521K	–	278
2025 Q1	$521K	Sell	30,102 -51,770	-63%	-$1.27M	0.14%	113
2024 Q4	$2.22M	Sell	81,872 -16,351	-17%	-$580K	0.35%	41
2024 Q3	$4.31M	Buy	98,223 +5,000	+5%	+$193K	1.03%	25
2024 Q2	$3.66M	Buy	93,223 +60,761	+187%	+$2.49M	0.93%	24
2024 Q1	$1.39M	Hold	32,462	–	–	0.28%	67
2023 Q4	$1.32M	Sell	32,462 -35,516	-52%	-$2.04M	0.28%	63
2023 Q3	$3.43M	Buy	+67,978	New	+$2.19M	0.76%	33

Other funds holding GPCR

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Jupiter Topco New York $245B AUM

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return

American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Wexford Capital's GPCR Position: Q2 2026 in Review

Wexford Capital held its Structure Therapeutics (GPCR) position steady in Q2 2026 at 13,709 shares worth $736K. The position accounts for 0.09% of the portfolio, ranked #80.

Wexford Capital first reported a position in GPCR in Q3 2023 and has held it in 10 quarters since. The position peaked at $4.31M in Q3 2024. 192 funds tracked by Wall St. Rank hold GPCR as of Q2 2026.

Wexford Capital held 13,709 shares of Structure Therapeutics worth $736K as of Q2 2026.
Wexford Capital left its Structure Therapeutics share count unchanged in Q2 2026.
Structure Therapeutics made up 0.09% of Wexford Capital's portfolio in Q2 2026, its #80 holding.
Wexford Capital first reported a position in Structure Therapeutics in Q3 2023 and has held it in 10 quarters since.
Wexford Capital's Structure Therapeutics position peaked at $4.31M in Q3 2024.
192 funds tracked by Wall St. Rank held Structure Therapeutics as of Q2 2026.

Based on Wexford Capital's 13F filing for Q2 2026, filed 14 Aug 2026.